Epistem plc (LSE: EHP), the UK biotechnology and personalized medicine company, has announced that their Contract Research Division’s histology and immunohistochemistry (IHC) laboratories have been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Contract Research Division provides solutions to support preclinical testing and clinical drug development programs within pharmaceutical and biotechnology organisations, providing valuable information on drug efficacy, target identification and protein biomarkers. The team provide a specialized histology and IHC service in UK Human TissueAuthority accredited laboratories, specialising in the development of novel methods for protein detection and localization. Epistem develops antibody novel labeling protocols and provides quality controlled data sets and publication quality images, complemented by use of the GLP compliant Ariol® and Aperio® PRECISION image analysis platforms.
GCLP status demonstrates that the Contract Research Division operates to standards set by the British Association of Research Quality Assurance that assures the reliability, quality and integrity of the work and results generated, and will allow studies to support the pivotal clinical phases of client drug development.
Catherine Booth, Co-founder and Managing Director of Epistem Contract Research Division commented:
Accreditation strengthens our clinical biomarker capabilities enabling us to support regulatory submissions from partners who use our technology and expertise globally.
For furtherinformation on the Company, please visit http://www.epistem.co.uk or contact:
| Dr Kathleen Mackay Public Relations Epistem plc |
T: +44 (0)161 606 7258 M: +44 (0) 7979 577886 E: [email protected] |
|
|
|
